Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura,The New England Journal of Medicine

当前位置： X-MOL 学术 › N. Engl. J. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2024-05-02 , DOI: 10.1056/nejmoa2314793
Marie Scully ₁ , Ana Antun ₁ , Spero R. Cataland ₁ , Paul Coppo ₁ , Claire Dossier ₁ , Nathalie Biebuyck ₁ , Wolf-Achim Hassenpflug ₁ , Karim Kentouche ₁ , Paul Knöbl ₁ , Johanna A. Kremer Hovinga ₁ , M. Fernanda López-Fernández ₁ , Masanori Matsumoto ₁ , Thomas L. Ortel ₁ , Jerzy Windyga ₁ , Indranil Bhattacharya ₁ , Michael Cronin ₁ , Hong Li ₁ , Björn Mellgård ₁ , Munjal Patel ₁ , Parth Patwari ₁ , Shan Xiao ₁ , Pinghai Zhang ₁ , Linda T. Wang ₁

Affiliation

Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived prod...

中文翻译：